Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 18.94 EUR 0.37% Market Closed
Market Cap: 18.6B EUR
Have any thoughts about
Bayer AG?
Write Note

Bayer AG
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bayer AG
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Bayer AG
XETRA:BAYN
Change in Working Capital
-€442m
CAGR 3-Years
38%
CAGR 5-Years
N/A
CAGR 10-Years
12%
ATAI Life Sciences NV
NASDAQ:ATAI
Change in Working Capital
$7.5m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck KGaA
XETRA:MRK
Change in Working Capital
-€497m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
MPH Health Care AG
XETRA:93M1
Change in Working Capital
-€9m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Change in Working Capital
-€92.6m
CAGR 3-Years
-12%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Change in Working Capital
-€3.6m
CAGR 3-Years
N/A
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Bayer AG
Glance View

Market Cap
18.6B EUR
Industry
Pharmaceuticals

Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue. Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.

BAYN Intrinsic Value
110.32 EUR
Undervaluation 83%
Intrinsic Value
Price

See Also

What is Bayer AG's Change in Working Capital?
Change in Working Capital
-442m EUR

Based on the financial report for Sep 30, 2024, Bayer AG's Change in Working Capital amounts to -442m EUR.

What is Bayer AG's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
12%

Over the last year, the Change in Working Capital growth was 92%. The average annual Change in Working Capital growth rates for Bayer AG have been 38% over the past three years , and 12% over the past ten years .

Back to Top